ROCK2 (Rho-associated protein kinase 2) inhibitors for the treatment of fibrosis.
ROCK2 is an intracellular kinase with multiple functions. ROCK2 signalling plays a key role in both the inflammatory component and the fibrotic re-modelling that drives disease progression. ROCK2 has been shown to be up-regulated in acute inflammatory injury, interacting with key molecular pathways and leading to the subsequent activation of cells in the fibrotic organ. By selectively targeting ROCK2, we aim to avoid the hypotensive side effects typically associated with systemic pan-ROCK inhibitors.
We aim to develop an orally administered selective ROCK2 inhibitor, focusing on diabetic nephropathy, IPF and NASH/ liver fibrosis